Checkpoint Therapeutics Inc (CKPT)
2.13
+0.08
(+3.90%)
USD |
NASDAQ |
Jul 02, 16:00
2.13
0.00 (0.00%)
After-Hours: 17:27
Checkpoint Therapeutics Research and Development Expense (TTM): 36.24M for March 31, 2024
Research and Development Expense (TTM) Chart
Historical Research and Development Expense (TTM) Data
| Date | Value |
|---|---|
| March 31, 2024 | 36.24M |
| December 31, 2023 | 43.57M |
| September 30, 2023 | 49.50M |
| June 30, 2023 | 52.87M |
| March 31, 2023 | 50.98M |
| December 31, 2022 | 49.82M |
| September 30, 2022 | 63.25M |
| June 30, 2022 | 63.76M |
| March 31, 2022 | 58.91M |
| December 31, 2021 | 48.45M |
| September 30, 2021 | 28.94M |
| June 30, 2021 | 22.10M |
| March 31, 2021 | 17.93M |
| December 31, 2020 | 16.35M |
| September 30, 2020 | 14.94M |
| June 30, 2020 | 16.29M |
| Date | Value |
|---|---|
| March 31, 2020 | 17.38M |
| December 31, 2019 | 19.32M |
| September 30, 2019 | 26.02M |
| June 30, 2019 | 29.97M |
| March 31, 2019 | 31.30M |
| December 31, 2018 | 33.65M |
| September 30, 2018 | 25.15M |
| June 30, 2018 | 22.26M |
| March 31, 2018 | 22.31M |
| December 31, 2017 | 19.08M |
| September 30, 2017 | 21.91M |
| June 30, 2017 | 21.67M |
| March 31, 2017 | 21.61M |
| December 31, 2016 | 20.27M |
| September 30, 2016 | 17.88M |
| June 30, 2016 | 16.66M |
R&D Expense Definition
R&D expense is a line item from many companies' income statements.
Research and Development Expense (TTM) Range, Past 5 Years
14.94M
Minimum
Sep 2020
63.76M
Maximum
Jun 2022
36.66M
Average
36.24M
Median
Mar 2024
Research and Development Expense (TTM) Benchmarks
| QuidelOrtho Corp | 243.70M |
| Anavex Life Sciences Corp | 38.28M |
| Ocugen Inc | 36.84M |
| Fortress Biotech Inc | 91.40M |
| NovaBay Pharmaceuticals Inc | 0.061M |